PL2911699T3 - Zmodyfikowane przeciwciało, koniugat przeciwciała i sposób ich otrzymywania - Google Patents

Zmodyfikowane przeciwciało, koniugat przeciwciała i sposób ich otrzymywania

Info

Publication number
PL2911699T3
PL2911699T3 PL13786322T PL13786322T PL2911699T3 PL 2911699 T3 PL2911699 T3 PL 2911699T3 PL 13786322 T PL13786322 T PL 13786322T PL 13786322 T PL13786322 T PL 13786322T PL 2911699 T3 PL2911699 T3 PL 2911699T3
Authority
PL
Poland
Prior art keywords
antibody
conjugate
preparation
modified
modified antibody
Prior art date
Application number
PL13786322T
Other languages
English (en)
Polish (pl)
Inventor
Floris Louis Van Delft
Remon VAN GEEL
Maria Antonia WIJDEVEN
Original Assignee
Synaffix B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50544942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2911699(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synaffix B.V. filed Critical Synaffix B.V.
Publication of PL2911699T3 publication Critical patent/PL2911699T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL13786322T 2012-10-23 2013-10-23 Zmodyfikowane przeciwciało, koniugat przeciwciała i sposób ich otrzymywania PL2911699T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261717187P 2012-10-23 2012-10-23
EP12189604 2012-10-23
EP13188607 2013-10-14
PCT/NL2013/050744 WO2014065661A1 (en) 2012-10-23 2013-10-23 Modified antibody, antibody-conjugate and process for the preparation thereof
EP13786322.1A EP2911699B2 (en) 2012-10-23 2013-10-23 Modified antibody, antibody-conjugate and process for the preparation thereof

Publications (1)

Publication Number Publication Date
PL2911699T3 true PL2911699T3 (pl) 2018-04-30

Family

ID=50544942

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13786322T PL2911699T3 (pl) 2012-10-23 2013-10-23 Zmodyfikowane przeciwciało, koniugat przeciwciała i sposób ich otrzymywania
PL21171679.0T PL3912642T3 (pl) 2012-10-23 2013-10-23 Zmodyfikowane przeciwciało, koniugat przeciwciała i sposób ich otrzymywania

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL21171679.0T PL3912642T3 (pl) 2012-10-23 2013-10-23 Zmodyfikowane przeciwciało, koniugat przeciwciała i sposób ich otrzymywania

Country Status (17)

Country Link
US (4) US10745488B2 (enExample)
EP (3) EP3912642B1 (enExample)
JP (3) JP6855661B2 (enExample)
CN (2) CN105142672B (enExample)
CY (1) CY1120041T1 (enExample)
DK (2) DK2911699T4 (enExample)
ES (2) ES2659270T3 (enExample)
FI (2) FI2911699T4 (enExample)
HR (2) HRP20230690T1 (enExample)
HU (2) HUE038285T2 (enExample)
LT (2) LT2911699T (enExample)
PL (2) PL2911699T3 (enExample)
PT (1) PT2911699T (enExample)
RS (2) RS64329B1 (enExample)
SI (2) SI3912642T1 (enExample)
SM (2) SMT202300208T1 (enExample)
WO (1) WO2014065661A1 (enExample)

Families Citing this family (178)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105142672B (zh) * 2012-10-23 2019-04-05 西纳福克斯股份有限公司 经修饰的抗体、抗体-缀合物及其制备方法
BR112015022585B1 (pt) * 2013-03-15 2023-04-04 Regeneron Pharmaceuticals, Inc Composto, composição farmacêutica, conjugado droga-anticorpo, e, uso dos mesmos
PL2991683T3 (pl) * 2013-05-02 2020-03-31 Glykos Finland Oy Koniugaty glikoproteiny lub glikanu z toksycznym ładunkiem
JP6608823B2 (ja) 2013-08-26 2019-11-20 レゲネロン ファーマシューティカルス，インコーポレーテッド マクロライドジアステレオマーを含む医薬組成物、その合成方法、及び治療上の使用
JP2016538878A (ja) * 2013-10-14 2016-12-15 シンアフィックス ビー．ブイ． 糖鎖工学的に操作された抗体、抗体コンジュゲート、及びそれらの調製方法
EP3058083B1 (en) * 2013-10-14 2018-04-11 SynAffix B.V. Modified glycoprotein, protein-conjugate and process for the preparation thereof
JP2016538877A (ja) * 2013-10-14 2016-12-15 シンアフィックス ビー．ブイ． 修飾糖タンパク質、タンパク質コンジュゲート及びそれらの調製方法
US20160303242A1 (en) 2013-12-09 2016-10-20 Durect Corporation Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same
EP3097080A1 (en) * 2014-01-24 2016-11-30 SynAffix B.V. Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne
JP2017505770A (ja) 2014-01-24 2017-02-23 シンアフィックス ビー．ブイ． （ヘテロ）アリール１，３−双極子化合物と（ヘテロ）シクロアルキンとの環化付加のためのプロセス
US10905678B2 (en) 2014-04-08 2021-02-02 University Of Georgia Research Foundation, Inc. Site-specific antibody-drug glycoconjugates and methods
AU2015282627B2 (en) 2014-06-30 2020-04-02 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
EP2974744A1 (en) 2014-07-16 2016-01-20 Stichting Katholieke Universiteit Strain-promoted oxidation controlled cycloaddition with high reaction rate
EP4148138A1 (en) 2014-08-04 2023-03-15 SynAffix B.V. Process for the modification of a glycoprotein using a beta-(1,4)-n-acetylgalactosaminyltransferase or a mutant thereof
CN112494657B (zh) * 2014-10-03 2025-02-11 西纳福克斯股份有限公司 磺酰胺接头、其缀合物及制备方法
CN107406463A (zh) * 2014-12-04 2017-11-28 细胞基因公司 生物分子共轭物
EP3240797A4 (en) * 2014-12-31 2018-08-01 Development Center for Biotechnology Site-specific conjugation through glycoproteins linkage and method thereof
US11559581B2 (en) * 2015-01-09 2023-01-24 Oxford University Innovation Limited Antibody conjugates and methods of making the antibody conjugates
KR20240142591A (ko) 2015-03-27 2024-09-30 리제너론 파아마슈티컬스, 인크. 메이탄시노이드 유도체, 이의 컨주게이트, 및 사용 방법
ES2659816T3 (es) 2015-04-23 2018-03-19 Synaffix B.V. Proceso para la modificación de una glucoproteína utilizando una glucosiltransferasa que es o que deriva de una (1,4)-n-acetilgalactosaminiltransferasa
WO2016172615A1 (en) * 2015-04-24 2016-10-27 University Of Delaware Synthetic n-acetyl-muramic acid derivatives and uses thereof
JP6993958B2 (ja) 2015-07-06 2022-02-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 多重特異性抗原結合分子およびその使用
EP3341735B1 (en) * 2015-08-26 2024-01-10 Vib Vzw Means and methods for monitoring inflammation
JP6892694B2 (ja) * 2015-10-07 2021-06-23 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ 癌選択性標識化及び標的指向化のためのトリガー活性型代謝糖前駆体
EP3165237B1 (en) 2015-11-03 2018-12-19 Industrial Technology Research Institute Antibody-drug conjugate (adc) and method for forming the same
JP2018536682A (ja) 2015-12-11 2018-12-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｅｇｆｒ及び／またはｅｒｂｂ３遮断に耐性のある腫瘍の成長を低減または防止するための方法
AU2017211120C1 (en) 2016-01-25 2021-10-07 Regeneron Pharmaceuticals, Inc. Maytansinoid derivatives, conjugates thereof, and methods of use
CN108495653A (zh) * 2016-01-27 2018-09-04 免疫医疗有限责任公司 用于制备具有定义的糖基化模式抗体的方法
ES2972511T3 (es) 2016-02-08 2024-06-13 Synaffix Bv Enzimas para el corte de glicoproteínas
JP2017197512A (ja) * 2016-02-08 2017-11-02 シンアフィックス ビー．ブイ． Ｃｄ３０腫瘍を標的化するための改善された治療指数を有する新規な抗体−コンジュゲート及び抗体−コンジュゲートの治療指数を改善するための方法
EP3413922B1 (en) 2016-02-08 2025-12-10 SynAffix B.V. Improved sulfamide linkers for use in bioconjugates
WO2017137457A1 (en) 2016-02-08 2017-08-17 Synaffix B.V. Antibody-conjugates with improved therapeutic index for targeting cd30 tumours and method for improving therapeutic index of antibody-conjugates
JP2019507741A (ja) 2016-02-08 2019-03-22 シンアフィックス ビー．ブイ． 治療において使用するためのスルファミドリンカーを含むバイオコンジュゲート
JP2017200902A (ja) * 2016-02-08 2017-11-09 シンアフィックス ビー．ブイ． Ｈｅｒ２腫瘍を標的化するための改善された治療指数を有する新規な抗体−コンジュゲート及び抗体−コンジュゲートの治療指数を改善するための方法
WO2017137458A1 (en) 2016-02-08 2017-08-17 Synaffix B.V. Antibody-conjugates with improved therapeutic index for targeting cd30 tumours and method for improving therapeutic index of antibody-conjugates
US11590239B2 (en) * 2016-02-08 2023-02-28 Synaffix B.V. Antibody-conjugates with improved therapeutic index for targeting CD30 tumours and method for improving therapeutic index of antibody-conjugates
SMT202100416T1 (it) 2016-03-02 2021-09-14 Eisai R&D Man Co Ltd Coniugati anticorpo-farmaco a base di eribulina e metodi di uso
EP3448891A1 (en) 2016-04-28 2019-03-06 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
WO2017191817A1 (ja) * 2016-05-02 2017-11-09 味の素株式会社 アジド基含有Ｆｃタンパク質
EP3472210A1 (en) * 2016-06-17 2019-04-24 Life Technologies Corporation Site-specific crosslinking of antibodies
EP4631529A2 (en) * 2016-06-28 2025-10-15 Ventana Medical Systems, Inc. Application of click chemistry for signal amplification in ihc and ish assays
WO2018003983A1 (ja) * 2016-07-01 2018-01-04 第一三共株式会社 ｈＡＮＰ－Ｆｃ含有分子コンジュゲート
WO2018002902A1 (en) 2016-07-01 2018-01-04 Glaxosmithkline Intellectual Property (No.2) Limited Antibody-drug conjugates and therapeutic methods using the same
MY199468A (en) * 2016-09-23 2023-10-31 Regeneron Pharma Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
KR20250114431A (ko) 2016-11-08 2025-07-29 리제너론 파마슈티칼스 인코포레이티드 스테로이드 및 이의 단백질-접합체
CN109996543A (zh) * 2016-11-14 2019-07-09 醣基生医股份有限公司 抗体药物复合体
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
CN110121365A (zh) 2016-12-29 2019-08-13 财团法人生物技术开发中心 制备糖蛋白-药物偶联物的方法
EP3577138A1 (en) 2017-02-06 2019-12-11 Innate Pharma Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
US11299509B2 (en) 2017-02-10 2022-04-12 The Board Of Trustees Of The University Of Illinois Trigger-activatable sugar conjugates for cancer-selective labeling and targeting
JP7678244B2 (ja) 2017-05-11 2025-05-16 ブイアイビー ブイゼットダブリュ 可変免疫グロブリンドメインのグリコシル化
CN110944718A (zh) 2017-05-18 2020-03-31 里珍纳龙药品有限公司 环糊精蛋白质药物偶联物
CA3063872A1 (en) 2017-05-18 2018-11-22 Regeneron Pharmaceuticals, Inc. Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
MA50546A (fr) 2017-06-07 2020-09-16 Regeneron Pharma Compositions et méthodes pour l'internalisation d'enzymes
EP3665161B1 (en) 2017-08-09 2023-09-27 Helmholtz-Zentrum für Infektionsforschung GmbH New targeted cytotoxic ratjadone derivatives and conjugates thereof
EP3441766B1 (en) * 2017-08-11 2020-03-11 Life Science Inkubator Sachsen GmbH & Co. KG Novel antibody conjugates suitable for use in discrete fluorescence quenching displacement immunoassays
CN117003875A (zh) * 2017-09-29 2023-11-07 第一三共株式会社 抗体或其功能性片段、多核苷酸、表达载体、宿主细胞、糖链重构抗体、药物组合物、应用
CA3080857A1 (en) 2017-11-07 2019-05-16 Regeneron Pharmaceuticals, Inc. Hydrophilic linkers for antibody drug conjugates
JP7165193B2 (ja) 2017-11-27 2022-11-02 パーデュー、ファーマ、リミテッド、パートナーシップ ヒト組織因子を標的とするヒト化抗体
CN111683686A (zh) * 2017-12-06 2020-09-18 西纳福克斯股份有限公司 烯二炔缀合物
CA3085356A1 (en) 2017-12-29 2019-07-04 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
JP7366028B2 (ja) 2018-01-08 2023-10-20 レゲネロン ファーマシューティカルス，インコーポレーテッド ステロイド及びその抗体コンジュゲート
KR102871690B1 (ko) 2018-04-30 2025-10-16 리제너론 파마슈티칼스 인코포레이티드 Her2 및/또는 aplp2에 결합하는 항체 및 이중특이적 항원-결합 분자 및 접합체 그리고 이들의 용도
KR20210008008A (ko) 2018-05-09 2021-01-20 리제너론 파마슈티칼스 인코포레이티드 항-msr1 항체 및 이의 사용 방법
AU2019269685B2 (en) 2018-05-17 2025-12-04 Regeneron Pharmaceuticals, Inc. Anti-CD63 antibodies, conjugates, and uses thereof
JP2019206491A (ja) * 2018-05-29 2019-12-05 国立研究開発法人理化学研究所 乳がんまたは胃がんの治療のための抗体−薬物複合体
ES2995219T3 (en) * 2018-06-15 2025-02-07 Shanghai Miracogen Inc Methods and materials for treating cancer
US11911484B2 (en) * 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
EP3829649A4 (en) * 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. ANTI-MUSCLE COMPLEXES AND THEIR USES
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
SG11202100934PA (en) 2018-08-02 2021-02-25 Dyne Therapeutics Inc Muscle targeting complexes and uses thereof for treating dystrophinopathies
CN112955154A (zh) * 2018-08-02 2021-06-11 达因疗法公司 肌肉靶向复合物及其用于治疗强直性肌营养不良的用途
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
SG11202100928QA (en) 2018-08-02 2021-02-25 Dyne Therapeutics Inc Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
WO2020094670A1 (en) * 2018-11-05 2020-05-14 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing trop-2
US12209180B2 (en) 2018-11-20 2025-01-28 Regeneron Pharmaceuticals, Inc. Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as LXR agonists
MA54545A (fr) 2018-12-21 2021-10-27 Regeneron Pharma Analogues de rifamycine et conjugués anticorps-médicament de ceux-ci
WO2020132658A2 (en) 2018-12-21 2020-06-25 Regeneron Pharmaceuticals, Inc. Tubulysins and protein-tubulysin conjugates
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
BR112021012482A2 (pt) 2018-12-27 2021-09-08 Glycomimetics, Inc. C-glicosídeos inibidores de galectina-3
EP3908323A2 (en) 2019-01-08 2021-11-17 Regeneron Pharmaceuticals, Inc. Traceless linkers and protein-conjugates thereof
GB201901608D0 (en) 2019-02-06 2019-03-27 Vib Vzw Vaccine adjuvant conjugates
JP2022523360A (ja) 2019-02-21 2022-04-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｍｅｔに結合する抗ｍｅｔ抗体および二特異性抗原結合分子を使用した眼癌の治療方法
KR20210141630A (ko) * 2019-03-25 2021-11-23 다이이찌 산쿄 가부시키가이샤 항 her2 항체-피롤로벤조디아제핀 유도체 콘주게이트
TWI856078B (zh) * 2019-03-25 2024-09-21 日商第一三共股份有限公司 抗體–吡咯并苯二氮呯衍生物結合物、其製造方法及其用途
CA3139180A1 (en) * 2019-03-27 2020-10-01 Daiichi Sankyo Company, Limited Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor
WO2020245229A1 (en) 2019-06-03 2020-12-10 Synaffix B.V. Acetal-based cleavable linkers
KR20220063185A (ko) 2019-09-16 2022-05-17 리제너론 파마슈티칼스 인코포레이티드 면역-pet 영상화를 위한 방사성 표지된 met 결합 단백질
US11814428B2 (en) 2019-09-19 2023-11-14 Regeneron Pharmaceuticals, Inc. Anti-PTCRA antibody-drug conjugates and uses thereof
US11833219B2 (en) * 2019-09-29 2023-12-05 Mabplex International Co., Ltd. Method for producing antibody-drug conjugate intermediate by addition of acid and use thereof
GB201917388D0 (en) * 2019-11-28 2020-01-15 Cambridge Entpr Ltd Novel linker compounds
GB201918279D0 (en) 2019-12-12 2020-01-29 Vib Vzw Glycosylated single chain immunoglobulin domains
TW202140075A (zh) * 2020-01-09 2021-11-01 美商梅爾莎納醫療公司 具有含肽之連接子的位置特異性抗體－藥物共軛體
WO2021144314A1 (en) 2020-01-13 2021-07-22 Synaffix B.V. Via cycloaddition bilaterally functionalized antibodies
JP2023509991A (ja) 2020-01-13 2023-03-10 シンアフィックス ビー．ブイ． 抗体及び免疫細胞エンゲージャーのコンジュゲート
CN115666656A (zh) 2020-01-13 2023-01-31 西纳福克斯股份有限公司 通过环加成双侧功能化抗体
MX2022008901A (es) 2020-01-24 2022-08-16 Regeneron Pharma Conjugados de proteinas-compuestos antivirales.
AU2021228225A1 (en) 2020-02-28 2022-09-01 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind HER2, and methods of use thereof
IL297027B2 (en) 2020-04-16 2025-08-01 Regeneron Pharma Antibody-drug conjugates prepared using diels-alder conjugation methods
JP2023528223A (ja) 2020-05-13 2023-07-04 ディスク・メディシン・インコーポレイテッド 骨髄線維症を処置するための抗ヘモジュベリン（ｈｊｖ）抗体
US20230183347A1 (en) 2020-05-25 2023-06-15 Foundation For Biomedical Research And Innovation At Kobe PD-1 Agonist-Containing Pharmaceutical Composition for Treating or PReventing TH2-Mediated Disease
CN111560078A (zh) * 2020-06-19 2020-08-21 联宁（苏州）生物制药有限公司 具有马来酰亚胺接头的双臂中间体及其合成方法
CN115867563B (zh) 2020-06-24 2025-06-27 里珍纳龙药品有限公司 微管溶素及蛋白质-微管溶素偶联物
EP4172141A1 (en) 2020-06-26 2023-05-03 Synaffix B.V. Methods for the preparation of linker payload constructs
IL299153A (en) 2020-07-13 2023-02-01 Regeneron Pharma Camptothecin analogs conjugated to a glutamine residue in protein, and their uses
NL2026400B1 (en) 2020-09-02 2022-05-04 Synaffix Bv Methods for the preparation of bioconjugates
EP4210767A1 (en) 2020-09-14 2023-07-19 Regeneron Pharmaceuticals, Inc. Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof
WO2022058395A1 (en) 2020-09-15 2022-03-24 Synaffix B.V. Antibody-exatecan conjugates
CA3195303A1 (en) 2020-10-16 2022-04-21 Gerardus Josephus BOONS Glycoconjugates
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
JP7767411B2 (ja) 2020-10-22 2025-11-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｆｇｆｒ２抗体及びその使用方法
NL2026947B1 (en) 2020-11-20 2022-07-01 Synaffix Bv Tyrosine-based antibody conjugates
WO2022136705A1 (en) 2020-12-24 2022-06-30 Synaffix B.V. Glycan-conjugated antibodies binding to fc-gamma receptor
EP4271816A4 (en) 2020-12-31 2025-04-02 Dyne Therapeutics, Inc. MUSCLE TARGETING COMPLEXES AND RELATED USES FOR THE TREATMENT OF MYOTONIC DYSTROPHY
CN117157107A (zh) 2021-02-08 2023-12-01 西纳福克斯股份有限公司 多功能抗体
CA3215049A1 (en) 2021-04-10 2022-10-13 Baiteng ZHAO Folr1 binding agents, conjugates thereof and methods of using the same
JP7742892B2 (ja) 2021-04-23 2025-09-22 ジェンマブ エー／エス 抗ｃｄ７０抗体、そのコンジュゲートおよびこれを使用する方法
MX2024000489A (es) 2021-07-09 2024-04-09 Dyne Therapeutics Inc Complejos dirigidos al musculo y formulaciones para el tratamiento de las distrofinopatías.
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
AU2022320713A1 (en) 2021-07-28 2023-11-09 Regeneron Pharmaceuticals, Inc. Protein-antiviral compound conjugates
WO2023065137A1 (en) * 2021-10-20 2023-04-27 Glyco-Therapy Biotechnology Co., Ltd. Site-specific glycoprotein conjugates and methods for making the same
KR102782629B1 (ko) * 2021-11-12 2025-03-19 닥터아이앤비(주) 생산 시간을 단축하고 안정성이 개선된 의약품 제조방법
KR20240101681A (ko) 2021-11-17 2024-07-02 디스크 메디슨, 인크. 신장 질환에 의한 빈혈을 치료하는 방법
WO2023129518A1 (en) 2021-12-29 2023-07-06 Regeneron Pharmaceuticals, Inc. Tubulysins and protein-tubulysin conjugates
CN118829449A (zh) 2022-01-12 2024-10-22 瑞泽恩制药公司 与蛋白中的谷氨酰胺残基缀合的喜树碱类似物及其用途
AU2023208050A1 (en) 2022-01-14 2024-07-04 Regeneron Pharmaceuticals, Inc. Verrucarin a derivatives and antibody drug conjugates thereof
US20250222124A1 (en) * 2022-01-27 2025-07-10 Glyco-Therapy Biotechnology Co., Ltd. Protein conjugates with multiple payloads and methods for making the same
US20250163488A1 (en) 2022-02-22 2025-05-22 Adc Therapeutics Sa Conjugation method involving a transglutaminase at the fc region comprising a trimmed n-glycan
EP4489855A1 (en) 2022-03-11 2025-01-15 Regeneron Pharmaceuticals, Inc. Anti-glp1r antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof
US20250205353A1 (en) 2022-03-23 2025-06-26 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing nectin-4
MX2024011518A (es) 2022-03-23 2024-09-24 Synaffix Bv Conjugados de anticuerpos para el tratamiento de tumores que expresan ptk7.
JP2025510700A (ja) 2022-03-23 2025-04-15 シンアフィックス ビー．ブイ． Ｔｒｏｐ－２を発現する腫瘍を標的化するための抗体コンジュゲート
AU2023237620A1 (en) 2022-03-23 2024-08-29 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen
CA3255934A1 (en) 2022-04-15 2023-10-19 Dyne Therapeutics, Inc. MUSCLE TARGETTING COMPLEXES AND FORMULATIONS FOR THE TREATMENT OF MYOTONIC DYSTROPHY
EP4285934A1 (en) 2022-05-30 2023-12-06 CER Groupe Modified trimannose-oligosacharides, bisected n-glycans comprising said trimannose core and method for obtaining them
US20240218011A1 (en) 2022-07-21 2024-07-04 Firefly Bio, Inc. Glucocorticoid receptor agonists and conjugates thereof
CN119997985A (zh) 2022-08-15 2025-05-13 西纳福克斯股份有限公司 蒽环类药物及其缀合物
EP4344707A1 (en) 2022-09-29 2024-04-03 Emergence Therapeutics AG New anti-nectin-4 antibody drug conjugates
WO2024118785A2 (en) 2022-11-30 2024-06-06 Regeneron Pharmaceuticals, Inc. Tlr7 agonists and antibody-drug-conjugates thereof
WO2024121123A1 (en) 2022-12-06 2024-06-13 Synaffix B.V. Synthesis of endo-bicyclononene
KR20250133813A (ko) 2022-12-21 2025-09-08 리제너론 파마슈티칼스 인코포레이티드 Adc 접합을 위한 토포이소머라아제 i 억제제의 전구약물 및 이의 사용 방법
AU2023409727A1 (en) * 2022-12-22 2025-08-07 Janssen Pharmaceutica Nv Methods of preparing antibody-polynucleotide conjugates
EP4389152A1 (en) 2022-12-23 2024-06-26 Synaffix B.V. Conjugates of pbd prodrugs
WO2024150074A2 (en) 2023-01-13 2024-07-18 Takeda Pharmaceutical Company Limited Coronavirus antibodies and therapeutic uses thereof
CN120390654A (zh) 2023-01-19 2025-07-29 上海盛迪医药有限公司 酪氨酸酶介导的蛋白定点偶联及其应用
EP4410313A1 (en) 2023-01-31 2024-08-07 Synaffix B.V. Homogeneous antibody-conjugates with high payload loading
EP4661914A1 (en) 2023-02-09 2025-12-17 Regeneron Pharmaceuticals, Inc. Antibody-drug conjugates via inverse electron demand diels-alder reactions
WO2024182714A1 (en) 2023-03-02 2024-09-06 Alloy Therapeutics, Inc. Anti-cd22 antibodies and uses thereof
CN121002057A (zh) * 2023-03-30 2025-11-21 启德医药科技（苏州）有限公司 二糖接头、含有该二糖接头的接头-有效载荷以及聚糖链重构的抗体-药物偶联物及其制备方法和用途
WO2024199432A1 (en) * 2023-03-30 2024-10-03 Genequantum Healthcare (Suzhou) Co., Ltd. Site-speicfic orthogonal bioconjugate modality and application thereof
EP4450489A1 (en) 2023-04-18 2024-10-23 Synaffix B.V. Stable 4-isoxazoline conjugates
WO2024218164A1 (en) 2023-04-17 2024-10-24 Synaffix B.V. Stable 4-isoxazoline conjugates
EP4450093A1 (en) 2023-04-17 2024-10-23 Synaffix B.V. Cleavable immune cell engagers
CN121039163A (zh) 2023-05-02 2025-11-28 瑞泽恩制药公司 抗人m-钙粘蛋白（cdh15）抗体、缀合物及其用于将遗传有效负载递送至肌肉细胞的用途
WO2024231447A1 (en) 2023-05-08 2024-11-14 Sanofi Glycosylation of immunoglobulin single variable domains
WO2024251826A1 (en) 2023-06-05 2024-12-12 Vib Vzw Glyco-engineered antibody-drug-conjugates comprising an oxime linker
WO2025014533A1 (en) 2023-07-10 2025-01-16 Regeneron Pharmaceuticals, Inc. Anti-human cacng1 antibody-drug conjugates and uses thereof
WO2025011557A1 (en) * 2023-07-10 2025-01-16 Surio Therapeutics Co. Ltd Functionalized auristatins, pharmaceutical compositions, and therapeutic applications
WO2025024334A1 (en) 2023-07-21 2025-01-30 Marrow Therapeutics, Inc. Hematopoietic cell targeting conjugates and related methods
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
TW202535954A (zh) 2023-09-26 2025-09-16 丹麥商珍美寶股份有限公司 Ｐｔｋ７結合劑、其共軛物及使用彼等之方法
EP4541376A1 (en) 2023-10-17 2025-04-23 ADC Therapeutics SA Antibody-drug conjugates
US20250171516A1 (en) 2023-11-03 2025-05-29 Regeneron Pharmaceuticals, Inc. Peptide acids as a glp1r agonist and antibody-drug conjugates thereof
WO2025117727A1 (en) 2023-11-29 2025-06-05 Regeneron Pharmaceuticals, Inc. Analogs of quinoxaline/quinoline cytotoxins, linker- payloads, protein-drug conjugates, and uses thereof
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物
EP4574174A1 (en) 2023-12-19 2025-06-25 Jack Elands Novel antibody-drug conjugates comprising an anti-(tcr)-cd3-complex binding antibody
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025163120A1 (en) 2024-02-01 2025-08-07 Adcytherix Sas ANTIBODY-DRUG CONJUGATES COMPRISING AN ANTI-INTEGRIN ΑVβ6 BINDING ANTIBODY
WO2025172468A1 (en) 2024-02-13 2025-08-21 Synaffix B.V. Method for producing azido-sugars and compounds obtained thereby
WO2025181219A1 (en) 2024-02-29 2025-09-04 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
WO2025238253A1 (en) 2024-05-16 2025-11-20 Synaffix B.V. Antibody-oligonucleotide conjugates

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20011671A7 (fi) 2001-08-20 2003-02-21 Carbion Oy Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
CA2510550A1 (en) 2003-01-10 2004-07-29 Pradman Qasba Catalytic domains of .beta./1,4)-galactosyltransferase i having altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods for their use
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
JP2007521047A (ja) 2003-10-29 2007-08-02 ビーエスエヌ メディカル，インク． 医療用包帯製品
US7332355B2 (en) * 2003-11-18 2008-02-19 California Institute Of Technology Method and compositions for the detection of protein glycosylation
US20070258986A1 (en) * 2003-11-19 2007-11-08 Govt of the US as represented by the secretary, Targeted Delivery System for Bioactive Agents
US7697764B2 (en) * 2003-11-21 2010-04-13 National University Corporation Kochi University Similar pattern searching apparatus, method of similar pattern searching, program for similar pattern searching, and fractionation apparatus
WO2005056783A1 (en) * 2003-12-05 2005-06-23 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Catalytic domains of beta(1,4)-galactosyltransferase i having altered metal ion specificity
JP5064037B2 (ja) 2004-02-23 2012-10-31 ジェネンテック， インコーポレイテッド 複素環式自壊的リンカーおよび結合体
US8431558B2 (en) 2004-11-01 2013-04-30 The Regents Of The University Of California Compositions and methods for modification of biomolecules
EP1991273B2 (en) 2006-02-10 2022-01-05 Life Technologies Corporation Labeling and detection of post translationally modified proteins
JP2009531289A (ja) * 2006-02-10 2009-09-03 ライフ テクノロジーズ コーポレーション オリゴ糖によるタンパク質の修飾及び標識方法
CA2647632C (en) * 2006-03-27 2017-06-27 University Of Maryland Biotechnology Institute Glycoprotein synthesis and remodeling by enzymatic transglycosylation
US8398956B2 (en) 2007-01-11 2013-03-19 Immunomedics, Inc. In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
WO2008143944A2 (en) * 2007-05-14 2008-11-27 Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Methods of glycosylation and bioconjugation
WO2009025646A1 (en) * 2007-08-22 2009-02-26 Government Of The U.S.A, As Represented By The Secretary, Department Of Health & Human Services Alpha 1-3 n-galactosyltransferase with altered donor specificities
WO2009025645A1 (en) * 2007-08-22 2009-02-26 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Beta 1,4-galactosyltransferases with altered donor and acceptor specificities, compositions and methods of use
CN101925366B (zh) 2007-11-21 2015-02-04 乔治亚大学研究基金公司 炔烃以及炔烃与1,3-偶极-官能化合物反应的方法
WO2009102820A2 (en) 2008-02-11 2009-08-20 Government Of The U.S A., As Represented By The Secretary, Department Of Health And Human Services Modified sugar substrates and methods of use
US7914904B2 (en) * 2008-03-25 2011-03-29 General Electric Company Component in a combustion system, and process for preventing slag, ash, and char buildup
AU2011215900A1 (en) * 2010-02-10 2012-07-26 Immunogen, Inc. CD20 antibodies and uses thereof
US8519122B2 (en) 2010-02-12 2013-08-27 The Regents Of The University Of California Compositions and methods for modification of biomolecules
DK2563753T6 (en) 2010-04-27 2016-04-04 Synaffix Bv Fused cyclooctynforbindelser and their use in metal-free click-reactions
EP2383374A1 (en) * 2010-04-29 2011-11-02 BASF Corporation Nano-particles containing carbon and a ferromagnetic metal or alloy
US20150072396A1 (en) 2011-03-04 2015-03-12 Life Technologies Corporation Compounds and Methods for Conjugation of Biomolecules
WO2012134925A1 (en) 2011-03-25 2012-10-04 Life Technologies Corporation Heterobifunctional esters for use in labeling target molecules
SG193324A1 (en) * 2011-04-01 2013-10-30 Wyeth Llc Antibody-drug conjugates
GB201115841D0 (en) 2011-09-13 2011-10-26 Genovis Ab Protein and method
CN105142672B (zh) * 2012-10-23 2019-04-05 西纳福克斯股份有限公司 经修饰的抗体、抗体-缀合物及其制备方法

Also Published As

Publication number Publication date
PT2911699T (pt) 2018-02-23
RS56953B1 (sr) 2018-05-31
DK2911699T4 (da) 2025-12-08
US12194107B2 (en) 2025-01-14
EP2911699B2 (en) 2025-09-10
JP7741788B2 (ja) 2025-09-18
HUE038285T2 (hu) 2018-10-29
ES2949376T3 (es) 2023-09-28
US20250177554A1 (en) 2025-06-05
HRP20180268T1 (hr) 2018-03-23
JP2015534996A (ja) 2015-12-07
ES2659270T3 (es) 2018-03-14
LT2911699T (lt) 2018-03-26
EP3912642A8 (en) 2022-01-05
FI2911699T4 (fi) 2025-12-09
JP2023017820A (ja) 2023-02-07
JP6855661B2 (ja) 2021-04-07
FI3912642T3 (fi) 2023-07-07
CN105142672B (zh) 2019-04-05
CN105142672A (zh) 2015-12-09
SMT201800096T1 (it) 2018-05-02
US20210163623A1 (en) 2021-06-03
EP3912642A1 (en) 2021-11-24
EP2911699B1 (en) 2017-11-15
JP7167071B2 (ja) 2022-11-08
HRP20230690T1 (hr) 2023-10-13
US20150320882A1 (en) 2015-11-12
DK2911699T3 (en) 2018-02-12
US10745488B2 (en) 2020-08-18
SI2911699T1 (en) 2018-04-30
LT3912642T (lt) 2023-07-25
EP2911699A1 (en) 2015-09-02
US9504758B2 (en) 2016-11-29
EP3335733A1 (en) 2018-06-20
SMT202300208T1 (it) 2023-09-06
PL3912642T3 (pl) 2023-08-14
HUE062385T2 (hu) 2023-10-28
CN110201186A (zh) 2019-09-06
WO2014065661A1 (en) 2014-05-01
RS64329B1 (sr) 2023-08-31
DK3912642T3 (da) 2023-06-26
US20150258210A1 (en) 2015-09-17
SI3912642T1 (sl) 2023-09-29
JP2020090526A (ja) 2020-06-11
CY1120041T1 (el) 2018-12-12
EP3912642B1 (en) 2023-04-12

Similar Documents

Publication Publication Date Title
SI3912642T1 (sl) Modificirano protitelo, konjugat protitelesa in postopek za pripravo le-teh
GB201115529D0 (en) Antibodies, uses and methods
GB201115280D0 (en) Antibodies, uses and methods
IL237625A0 (en) Antibodies against m-cam, preparations containing them and their uses
IL236348A0 (en) Anti-Jagad antibodies, preparations containing them and their uses
AU2013355931A1 (en) Anti-folr1 antibody
IL235807A0 (en) Immunoprecipitates containing anti–cd79b antibodies
IL234719A0 (en) Anti-pmel17 antibodies and immunoconjugates
EP2879708A4 (en) ANTIBODY AND ANTI-ETBR IMMUNOCONJUGATES
SG11201405881TA (en) Anti-lgr5 antibodies and immunoconjugates
SG11201500096YA (en) Immunoconjugates comprising anti - cd79b antibodies
IL235004A0 (en) Antibodies against fgfr2, preparations containing them and their uses
IL254416B (en) Anti-asic1 antibodies and their uses
ZA201405554B (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
ZA201504538B (en) Anti-lamp1 antibodies and antibody drug conjugates ,and uses thereof
PL2650310T3 (pl) Przeciwciało przeciw-ADAMTS-5, jego pochodne i zastosowania
PL2855530T3 (pl) Przeciwciała przeciwko transglutaminazie 2
EP2879711A4 (en) ANTI-ETBR ANTIBODIES AND IMMUNOCONJUGATES
PL398018A1 (pl) Nowa diacylo-sn-glicero-3-fosfocholina oraz sposób jej otrzymywania
PL398021A1 (pl) Nowa diacylo-sn-glicero-3-fosfocholina oraz sposób jej otrzymywania
PT3912642T (pt) Anticorpo modificado e ligado de anticorpo e processo para a preparação dos mesmos
GB201208372D0 (en) Antibodies and uses thereof
GB201209584D0 (en) Modified antibodies